Kevin Kabler is a partner in Goodwin’s Technology and Life Sciences groups. His practice focuses on developing and implementing value-creating patent portfolio strategies for emerging and mature life sciences companies. Dr. Kabler integrates with his clients, fully understands their business goals, and works directly with them to build comprehensive and efficient patent portfolio strategies to advance those goals.
Dr. Kabler’s practice also involves strategic patent counseling and intellectual property due diligence for his life sciences clients, including companies and investors. His diligence work includes acting as lead patent counsel on behalf of his clients in mergers, acquisitions, and strategic partnership formation with pharmaceutical and biotechnology companies. He has extensive experience advising his clients in assessing competitive landscapes, complex intellectual property assets, associated risks, and thoughtful mitigation of those risks. His deep diligence experience and strategic insights have made him one of the most preferred diligence counsel in California for life sciences companies and their investors.
Prior to joining Goodwin in 2019, Dr. Kabler was a partner at Fenwick & West LLP. Before joining Fenwick & West, he was a post-doctoral fellow in the laboratory of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.
Dr. Kabler’s representative experience includes IP due diligence in the following deals:
- ArsenalBio on its $70 million collaboration with Bristol Myers Squibb
- Octave Bioscience in its $32 million Series B financing
- Senti Biosciences in its $105 million Series B financing
- Arrowmark Partners and RA Capital in its $42.5 million Series E investment in Adagio Medical
- Forty Seven, Inc. in its $4.9 billion acquisition by Gilead
- Pionyr Immunotherapeutics Inc. in its $275 million exclusive option to be acquired by Gilead
- Connect Biopharma in its $115 million Series C financing
- Gritstone Oncology in its (i) initial public offering*, (ii) follow on public offering, and (iii) collaboration with bluebird bio, in which bluebird paid $20 million upfront in return for 10 tumor-specific targets and T-cell receptors (TCRs)
- Arsenal Biosciences in its $86 million Series A financing
- Iconic Therapeutics in its exclusive option and license agreement with Exelixis, Inc. to advance an innovative next-generation antibody-drug conjugate (ADC) program
- ArrowMark Partners in its $110 million Series B investment in Precision Biosciences*
- Pionyr Immunotherapeutics Inc. in its $62 million Series B financing*
- Gritstone Oncology in its $97.5 Million Series B financing*
- ProNAi Therapeutics in its $158.4 Million initial public offering*
* Denotes experience prior to joining Goodwin
University of California College of the Law, San Francisco
(magna cum laude, Order of the Coif, Thurston Honor Society)
Baylor College of Medicine
Kansas State University
- U.S. Patent and Trademark Office (USPTO)